Literature DB >> 20420337

Impact of tinnitus on quality of life, loudness and pitch match, and high-frequency audiometry.

Raquel Prestes1, G Daniela.   

Abstract

Our objective was to compare quality of life, high-frequency audiometry, and loudness-pitch match in individuals with tinnitus with and without hearing loss. We divided 52 individuals into two groups: one with hearing impairment (HI; n = 24) and the other with no hearing loss (NL; n = 28). All participants underwent loudness-pitch match and high-frequency audiometry and responded to the Tinnitus Handicap Inventory (THI) and World Health Organization Quality of Life (WHOQOL) questionnaires. On high-frequency audiometry, older individuals required 77.15% more intensity than did young individuals. On the THI questionnaire, individuals in the NL group exhibited mild handicap, whereas those in the HI group exhibited moderate handicap. On the WHOQOL questionnaires, the HI group demonstrated greater impairment on the physical and psychological domains than did the NL group. Individuals with HI experienced greater discomfort with tinnitus. On high-frequency audiometry, individuals with tinnitus and HI exhibited higher thresholds, with complete hearing loss at some frequencies. The WHOQOL and THI questionnaires revealed that individuals with HI experienced a poorer quality of life than did those with normal hearing.

Entities:  

Mesh:

Year:  2009        PMID: 20420337

Source DB:  PubMed          Journal:  Int Tinnitus J        ISSN: 0946-5448


  8 in total

1.  [Psychometric instruments for the diagnosis of tinnitus].

Authors:  C Seydel; N Zirke; H Haupt; A Szczepek; H Olze; B Mazurek
Journal:  HNO       Date:  2012-08       Impact factor: 1.284

2.  Atorvastatin is associated with reduced cisplatin-induced hearing loss.

Authors:  Katharine A Fernandez; Paul Allen; Maura Campbell; Brandi Page; Thomas Townes; Chuan-Ming Li; Hui Cheng; Jaylon Garrett; Marcia Mulquin; Anna Clements; Deborah Mulford; Candice Ortiz; Carmen Brewer; Judy R Dubno; Shawn Newlands; Nicole C Schmitt; Lisa L Cunningham
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

Review 3.  Neuromodulation for tinnitus treatment: an overview of invasive and non-invasive techniques.

Authors:  Nicole Peter; Tobias Kleinjung
Journal:  J Zhejiang Univ Sci B       Date:  2018-03-12       Impact factor: 3.066

4.  Hungarian adaptation of the Tinnitus Handicap Inventory: reliability and validity.

Authors:  Beata Bencsik; László Tamás; Krisztina Trimmel; Adrienne Stauder
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-27       Impact factor: 2.503

5.  Is it necessary to do temporal bone computed tomography of the internal auditory canal in tinnitus with normal hearing?

Authors:  Tolgar Lutfi Kumral; Guven Yıldırım; Huseyin Baki Yılmaz; Seckin Ulusoy; Guler Berkiten; Suzan Deniz Onol; Yusuf Ozturkçu; Yavuz Uyar
Journal:  ScientificWorldJournal       Date:  2013-11-26

6.  Validation of PRISM (Pictorial Representation of Illness and Self Measure) as a novel visual assessment tool for the burden of suffering in tinnitus patients.

Authors:  Nicole Peter; Tobias Kleinjung; Lukas Horat; Sabine Schmidt-Weitmann; Martin Meyer; Stefan Büchi; Steffi Weidt
Journal:  Health Qual Life Outcomes       Date:  2016-03-22       Impact factor: 3.186

7.  The Relevance of the High Frequency Audiometry in Tinnitus Patients with Normal Hearing in Conventional Pure-Tone Audiometry.

Authors:  Veronika Vielsmeier; Astrid Lehner; Jürgen Strutz; Thomas Steffens; Peter M Kreuzer; Martin Schecklmann; Michael Landgrebe; Berthold Langguth; Tobias Kleinjung
Journal:  Biomed Res Int       Date:  2015-10-25       Impact factor: 3.411

8.  Study of the relationship between the degree of tinnitus annoyance and the presence of hyperacusis.

Authors:  Alexandre Caixeta Guimarães; Guilherme Machado de Carvalho; Márcia Maria de Freitas Dias Voltolini; Carlos Eduardo Monteiro Zappelini; Raquel Mezzalira; Guita Stoler; Jorge Rizzato Paschoal
Journal:  Braz J Otorhinolaryngol       Date:  2014 Jan-Feb
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.